These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

482 related articles for article (PubMed ID: 32755557)

  • 1. Brain uptake pharmacokinetics of incretin receptor agonists showing promise as Alzheimer's and Parkinson's disease therapeutics.
    Salameh TS; Rhea EM; Talbot K; Banks WA
    Biochem Pharmacol; 2020 Oct; 180():114187. PubMed ID: 32755557
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparing regional brain uptake of incretin receptor agonists after intranasal delivery in CD-1 mice and the APP/PS1 mouse model of Alzheimer's disease.
    Abdulhameed N; Babin A; Hansen K; Weaver R; Banks WA; Talbot K; Rhea EM
    Alzheimers Res Ther; 2024 Aug; 16(1):173. PubMed ID: 39085976
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain uptake pharmacokinetics of albiglutide, dulaglutide, tirzepatide, and DA5-CH in the search for new treatments of Alzheimer's and Parkinson's diseases.
    Rhea EM; Babin A; Thomas P; Omer M; Weaver R; Hansen K; Banks WA; Talbot K
    Tissue Barriers; 2024 Oct; 12(4):2292461. PubMed ID: 38095516
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Novel Dual GLP-1/GIP Receptor Agonist DA-CH5 Is Superior to Single GLP-1 Receptor Agonists in the MPTP Model of Parkinson's Disease.
    Zhang L; Zhang L; Li Y; Li L; Melchiorsen JU; Rosenkilde M; Hölscher C
    J Parkinsons Dis; 2020; 10(2):523-542. PubMed ID: 31958096
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A novel GLP-1/GIP dual agonist is more effective than liraglutide in reducing inflammation and enhancing GDNF release in the MPTP mouse model of Parkinson's disease.
    Yuan Z; Li D; Feng P; Xue G; Ji C; Li G; Hölscher C
    Eur J Pharmacol; 2017 Oct; 812():82-90. PubMed ID: 28666800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antidiabetic agents as a novel treatment for Alzheimer's and Parkinson's disease.
    Nowell J; Blunt E; Gupta D; Edison P
    Ageing Res Rev; 2023 Aug; 89():101979. PubMed ID: 37328112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Two novel dual GLP-1/GIP receptor agonists are neuroprotective in the MPTP mouse model of Parkinson's disease.
    Feng P; Zhang X; Li D; Ji C; Yuan Z; Wang R; Xue G; Li G; Hölscher C
    Neuropharmacology; 2018 May; 133():385-394. PubMed ID: 29462693
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Brain insulin resistance: role in neurodegenerative disease and potential for targeting.
    Hölscher C
    Expert Opin Investig Drugs; 2020 Apr; 29(4):333-348. PubMed ID: 32175781
    [No Abstract]   [Full Text] [Related]  

  • 9. Incretin analogues that have been developed to treat type 2 diabetes hold promise as a novel treatment strategy for Alzheimer's disease.
    Holscher C
    Recent Pat CNS Drug Discov; 2010 Jun; 5(2):109-17. PubMed ID: 20337586
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A novel dual GLP-1/GIP receptor agonist alleviates cognitive decline by re-sensitizing insulin signaling in the Alzheimer icv. STZ rat model.
    Shi L; Zhang Z; Li L; Hölscher C
    Behav Brain Res; 2017 Jun; 327():65-74. PubMed ID: 28342971
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin-based drugs as potential therapy for neurodegenerative diseases: current status and perspectives.
    Ferrari F; Moretti A; Villa RF
    Pharmacol Ther; 2022 Nov; 239():108277. PubMed ID: 36064147
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment.
    Kopp KO; Glotfelty EJ; Li Y; Greig NH
    Pharmacol Res; 2022 Dec; 186():106550. PubMed ID: 36372278
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glucagon-like peptide 1 and glucose-dependent insulinotropic peptide hormones and novel receptor agonists protect synapses in Alzheimer's and Parkinson's diseases.
    Hölscher C
    Front Synaptic Neurosci; 2022; 14():955258. PubMed ID: 35965783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GIP has neuroprotective effects in Alzheimer and Parkinson's disease models.
    Zhang ZQ; Hölscher C
    Peptides; 2020 Mar; 125():170184. PubMed ID: 31705913
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs developed to treat diabetes, liraglutide and lixisenatide, cross the blood brain barrier and enhance neurogenesis.
    Hunter K; Hölscher C
    BMC Neurosci; 2012 Mar; 13():33. PubMed ID: 22443187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Drugs developed for treatment of diabetes show protective effects in Alzheimer's and Parkinson's diseases.
    Hölscher C
    Sheng Li Xue Bao; 2014 Oct; 66(5):497-510. PubMed ID: 25331995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neuroprotective and restorative properties of the GLP-1/GIP dual agonist DA-JC1 compared with a GLP-1 single agonist in Alzheimer's disease.
    Salles GN; Calió ML; Hölscher C; Pacheco-Soares C; Porcionatto M; Lobo AO
    Neuropharmacology; 2020 Jan; 162():107813. PubMed ID: 31628935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Novel DA-CH3 Dual Incretin Restores Endoplasmic Reticulum Stress and Autophagy Impairments to Attenuate Alzheimer-Like Pathology and Cognitive Decrements in the APPSWE/PS1ΔE9 Mouse Model.
    Panagaki T; Gengler S; Hölscher C
    J Alzheimers Dis; 2018; 66(1):195-218. PubMed ID: 30282365
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Glucagon-like peptide-1 class drugs show clear protective effects in Parkinson's and Alzheimer's disease clinical trials: A revolution in the making?
    Hölscher C
    Neuropharmacology; 2024 Aug; 253():109952. PubMed ID: 38677445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acylation of the Incretin Peptide Exendin-4 Directly Impacts Glucagon-Like Peptide-1 Receptor Signaling and Trafficking.
    Lucey M; Ashik T; Marzook A; Wang Y; Goulding J; Oishi A; Broichhagen J; Hodson DJ; Minnion J; Elani Y; Jockers R; Briddon SJ; Bloom SR; Tomas A; Jones B
    Mol Pharmacol; 2021 Oct; 100(4):319-334. PubMed ID: 34315812
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.